Full Text View
Tabular View
No Study Results Posted
Related Studies
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder (MANIA)
This study has been completed.
Study NCT00672490   Information provided by AstraZeneca
First Received: May 2, 2008   Last Updated: February 11, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Mania in Bipolar Disorder
Additional conditions recognized in this trial
Bipolar Disorder
More general conditions related to this trial
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders
Interventions listed in this trial
Quetiapine Fumarate
Lithium
Additional drug interventions recognized in this trial
Lithium Carbonate
Quetiapine
More general drug interventions related to this trial
Antidepressive Agents
Antimanic Agents
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services